Dupilumab study for chronic sinus disease with nasal polyps
Treatments studied
Part of Ear, nose & throat, Immune system & allergy clinical trials.
This study looks at how dupilumab (an injection medicine) helps people with chronic rhinosinusitis with nasal polyps, including how well it works across different ethnic backgrounds. You may be able to join if you’ve been diagnosed and you can get dupilumab through insurance or a patient assistance program.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older with a doctor diagnosis of chronic sinus disease with nasal polyps
- You must be eligible to use dupilumab (Dupixent) based on its usual medical indication
- You must be able to get dupilumab covered by insurance or through Dupixent MyWay
- You should not have had another biologic medicine in the last 3 months
- You should not be pregnant
- You must not have certain related conditions like allergic fungal sinus disease, cystic fibrosis, EGPA/Churg-Strauss, or inverted papilloma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dupilumab, a medication given as an injection, helps improve the lining of the nose in people with chronic sinus inflammation and nasal polyps. If you have nasal polyps and are about to start dupilumab, or if you have sinusitis without polyps, you may be eligible to join.
This study is testing if a drug called Dupilumab affects your immune system when you have both asthma and nasal polyps and are having sinus surgery. It might help doctors understand how to better treat these conditions together.
This trial studies whether dupilumab can improve smell in adults whose nasal polyps are causing long-lasting smell loss. It may help learn how well the treatment restores smell, so future patients can benefit sooner.
This trial tests if patients with chronic sinusitis and nasal polyps can safely reduce how often they take their biologic medication (dupilumab or mepolizumab) after their disease has been partly controlled for at least a year.
This trial tests a new antibody medicine (CM326) for people with chronic sinusitis and nasal polyps whose symptoms persist despite standard treatments like nasal sprays. It aims to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new biologic drug (tezepelumab) to see if it improves symptoms in people with both chronic sinusitis with nasal polyps and severe asthma. The goal is to reduce inflammation and help you breathe better. Participants must not have had prior sinus surgery.
Hear when a new Chronic Rhinosinusitis With Nasal Polyps trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.